Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077695918> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2077695918 endingPage "A339" @default.
- W2077695918 startingPage "A338" @default.
- W2077695918 abstract "Several studies have demonstrated that Risperidone Long-Acting Injectable (RLAI) reduces psychotic relapses, hospitalization and resources used among schizophrenic patients with poor adherence to oral medication. However, the magnitude of such reductions depends upon the baseline relapse rate. This study is aimed at identifying the thresholds of relapse risk at which RLAI is cost-effective, compared to Oral Olanzapine (OO), Oral Quetiapine (OQ) and Haloperidol Decanoate (HD). A Markov model was developed to simulate the natural history of schizophrenia for patients who have poor adherence and high risk of relapse with oral medication. The strategies compared were starting treatment with RLAI, OO, OQ or HD. Relapse probabilities, adherence levels, side effects and treatment switching were derived from long-term observational data. Resource use and costs were obtained from Mexican public institutions. Patients transit through different health states in the model on a monthly basis over a 10-year time horizon. Incremental cost and effectiveness outcomes were discounted at 3% annually. In patients with Baseline Annual Relapse Rate (BARR) equal or greater than 72.5%, RLAI is the most effective and less costly treatment (cost-saving) if effectiveness is measured in terms of QALYs or relapses averted. In this case, RLAI produces 0.27 (5.13-5.4) additional discounted QALYs and avoids 3.97 relapses, compared to OO. According to the WHO Commission on Macroeconomics and Health, RLAI is highly cost-effective (≤1xGDP per-capita/QALY gained) in patients with a BARR between 63% and 72.5% and cost-effective (≤3xGDP per-capita /QALY gained) in patients with a BARR between 35% and 63%. In all published naturalistic studies comparing RLAI with oral medication, where the selection of patients to receive RLAI is left to the physicians, the BARR is greater than 0.71, which suggest that using RLAI in Mexico with similar criteria of patient selection would result in a cost-saving strategy." @default.
- W2077695918 created "2016-06-24" @default.
- W2077695918 creator A5056372118 @default.
- W2077695918 creator A5049800215 @default.
- W2077695918 date "2012-11-01" @default.
- W2077695918 modified "2023-10-12" @default.
- W2077695918 title "PMH28 Using Cost-Effectiveness Analysis to Define the Optimal Group of Patients to Benefit From Risperidone Long-Acting Injectable" @default.
- W2077695918 doi "https://doi.org/10.1016/j.jval.2012.08.818" @default.
- W2077695918 hasPublicationYear "2012" @default.
- W2077695918 type Work @default.
- W2077695918 sameAs 2077695918 @default.
- W2077695918 citedByCount "0" @default.
- W2077695918 crossrefType "journal-article" @default.
- W2077695918 hasAuthorship W2077695918A5049800215 @default.
- W2077695918 hasAuthorship W2077695918A5056372118 @default.
- W2077695918 hasBestOaLocation W20776959181 @default.
- W2077695918 hasConcept C112930515 @default.
- W2077695918 hasConcept C118552586 @default.
- W2077695918 hasConcept C126322002 @default.
- W2077695918 hasConcept C127598652 @default.
- W2077695918 hasConcept C187212893 @default.
- W2077695918 hasConcept C23131810 @default.
- W2077695918 hasConcept C2776412080 @default.
- W2077695918 hasConcept C2776619155 @default.
- W2077695918 hasConcept C2780057945 @default.
- W2077695918 hasConcept C2780634440 @default.
- W2077695918 hasConcept C2908647359 @default.
- W2077695918 hasConcept C3019080777 @default.
- W2077695918 hasConcept C71924100 @default.
- W2077695918 hasConcept C99454951 @default.
- W2077695918 hasConceptScore W2077695918C112930515 @default.
- W2077695918 hasConceptScore W2077695918C118552586 @default.
- W2077695918 hasConceptScore W2077695918C126322002 @default.
- W2077695918 hasConceptScore W2077695918C127598652 @default.
- W2077695918 hasConceptScore W2077695918C187212893 @default.
- W2077695918 hasConceptScore W2077695918C23131810 @default.
- W2077695918 hasConceptScore W2077695918C2776412080 @default.
- W2077695918 hasConceptScore W2077695918C2776619155 @default.
- W2077695918 hasConceptScore W2077695918C2780057945 @default.
- W2077695918 hasConceptScore W2077695918C2780634440 @default.
- W2077695918 hasConceptScore W2077695918C2908647359 @default.
- W2077695918 hasConceptScore W2077695918C3019080777 @default.
- W2077695918 hasConceptScore W2077695918C71924100 @default.
- W2077695918 hasConceptScore W2077695918C99454951 @default.
- W2077695918 hasIssue "7" @default.
- W2077695918 hasLocation W20776959181 @default.
- W2077695918 hasOpenAccess W2077695918 @default.
- W2077695918 hasPrimaryLocation W20776959181 @default.
- W2077695918 hasRelatedWork W1948712038 @default.
- W2077695918 hasRelatedWork W2015648323 @default.
- W2077695918 hasRelatedWork W2063786523 @default.
- W2077695918 hasRelatedWork W2134153999 @default.
- W2077695918 hasRelatedWork W2143170327 @default.
- W2077695918 hasRelatedWork W2189076637 @default.
- W2077695918 hasRelatedWork W2348448619 @default.
- W2077695918 hasRelatedWork W2363031053 @default.
- W2077695918 hasRelatedWork W3183294090 @default.
- W2077695918 hasRelatedWork W2553614246 @default.
- W2077695918 hasVolume "15" @default.
- W2077695918 isParatext "false" @default.
- W2077695918 isRetracted "false" @default.
- W2077695918 magId "2077695918" @default.
- W2077695918 workType "article" @default.